Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study

Roman Hajek, Prof, MD PhD, Jiri Minarik, MD PhD, Jan Straub, MD, Ludek Pour, MD, Alexandra Jungova, Jesus G. Berdeja, MD, Mario Boccadoro, Lucie Brožová, MSc, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Frits van Rhee, MD PhD, Jorge Vela-Ojeda, MD PhD, Michael A. Thompson, MD PhD FASCO, Rafat Abonour, MD, Ajai Chari, MD, Gordon Cook, MB ChB, PhD FRCP(Glas), FRCPath, Caitlin L. Costello, MD, Faith E. Davies, MD, Vania T.M. Hungria, MD PhD, Hans C. Lee, MD, Xavier Leleu, MD PhD, Noemi Puig, MD PhD, Robert M. Rifkin, MD, Evangelos Terpos, MD PhD, Saad Z. Usmani, MD FACP, Katja C. Weisel, MD, Jeffrey A. Zonder, Magda Bařinová, MSc, Matyáš Kuhn, MSc, Jiri Silar, MSc, Lenka Capkova, Kenny Galvez, MD, Jin Lu, MDProf, Tomas Skacel, MD, Jennifer Elliott, Brittany Demers, BS, BA, Dawn Marie Stull, Pharm.D., BCOP, Kaili Ren, PhD, Vladimir Maisnar, MD PhD MBA

Blood (2019) 134 (Supplement_1): 1845.

https://doi.org/10.1182/blood-2019-126606

Published: 2019

Journal Articles

Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study

Blood (2019) 134 (Supplement_1): 1887.

https://doi.org/10.1182/blood-2019-125749

Published: 2019

Journal Articles

Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R MM), Indicates Preferential Expansion of CD8+ T Cell Central Memory Cell Subset

Enrique Zudaire, PhD, Deepu Madduri, MD, Saad Z. Usmani, MD FACP, Andrzej Jakubowiak, MD PhD, Jesus G. Berdeja, MD, Dong Geng, Syed Rizvi, MD, Tonia Nesheiwat, Jordan M Schecter, MD, Jenna D. Goldberg, MD, Arnob Banerjee, MD, Alicia J. Allred, PhD, Indrajeet Singh, PhD, Raluca Verona, PhD, Ian McCaffery, PhD, Sundar Jagannath

Blood (2019) 134 (Supplement_1): 928.

https://doi.org/10.1182/blood-2019-127309

Published: 2019

Journal Articles

Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

Shaji Kumar, MD, Meletios A Dimopoulos, Efstathios Kastritis, MD, Evangelos Terpos, Hareth Nahi, Hartmut Goldschmidt, MD, Jens Hillengass, MD, Xavier Leleu, Meral Beksac, MD, Melissa Alsina, MD, Albert Oriol, MD, Michele Cavo, MD, Enrique M. Ocio, MD PhD, Maria Victoria Mateos, Elizabeth K. O'Donnell, MD, Ravi Vij, MD MBA, Henk M. Lokhorst, MD PhD, Niels W.C.J. van de Donk, MD PhD, Chang-Ki Min, Tomer Mark, MD MSc, Ingemar Turesson, MD, PhD, Markus Hansson, MD, Heinz Ludwig, Sundar Jagannath, MD, Michel Delforge, MD PhD, Charalampia Kyriakou, MD PhD, Parameswaran Hari, MBBS, MD MRCP, Ulf-Henrik Mellqvist, MD PhD, Saad Z Usmani, MD FACP, Dominik Dytfeld, MD PhD, Ashraf Z Badros, MD, Philippe Moreau, Kihyun Kim, MD PhD, Paula Rodriguez Otero, MD, Jae Hoon Lee, MD, Chaim Shustik, MD, Daniel Waller, PhD, Wee Joo Chng, MD PhD, Shuji Ozaki, MD PhD, Je-Jung Lee, Javier de la Rubia, Hyeon Seok Eom, MD PhD, Laura Rosinol, MD PhD, Juan José Lahuerta, MD PhD, Anna Sureda, MD PhD, Jin Seok Kim, MD PhD, Brian G.M. Durie, MD

Blood (2016) 128 (22): 4414.

https://doi.org/10.1182/blood.V128.22.4414.4414

Published: 2016

Journal Articles

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

Saad Z Usmani, MD FACP, Hareth Nahi, Maria-Victoria Mateos, MD PhD, Henk M. Lokhorst, MD PhD, Ajai Chari, MD, Jonathan L. Kaufman, MD, Philippe Moreau, Albert Oriol, MD, Torben Plesner, Professor, Lotfi Benboubker, MD PhD, Peter Hellemans, MD, Tara Masterson, Pamela L Clemens, PhD, Tahamtan Ahmadi, MD, Kevin Liu, Jesús San-Miguel, MD PhD

Blood (2016) 128 (22): 1149.

https://doi.org/10.1182/blood.V128.22.1149.1149

Published: 2016

Journal Articles

Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux

Saad Z Usmani, MD FACP, Meletios A Dimopoulos, Andrew Belch, Darrell White, MD, Lofti Benboubker, Gordon Cook, MD PhD, Merav Leiba, MD, James Morton, MBBS, BSc(MD, FRACP, FRCPA, P. Joy Ho, Kihyun Kim, Naoki Takezako, MD PhD, Nushmia Z Khokhar, Mary Guckert, Kaida Wu, MD PhD, Xiang Qin, Tineke Casneuf, Christopher Chiu, PhD, A. Kate Sasser, Jesús San-Miguel, MD PhD

Blood (2016) 128 (22): 1151.

https://doi.org/10.1182/blood.V128.22.1151.1151

Published: 2016

Journal Articles

Peripheral Immune Profile and Minimal Residual Disease (MRD) Burden Following Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM)

David Foureau, PhD, Qing Zhang, PhD, Tammy D Cogdill, NP, Adina S Wynn, Nury M. Steuerwald, PhD, Lawrence J. Druhan, PhD, Fei Guo, Katherine Rigby, Kyle L Madden, BS, James T Symanowski, PhD, Belinda R. Avalos, MD, Edward A. Copelan, MD FACP, Saad Z Usmani, MD FACP, Manisha Bhutani, MD

Blood (2016) 128 (22): 378.

https://doi.org/10.1182/blood.V128.22.378.378

Published: 2016

Journal Articles

Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients: The Insight-MM Study

Blood (2016) 128 (22): 5681.

https://doi.org/10.1182/blood.V128.22.5681.5681

Published: 2016

Journal Articles

Results of an Early Access Treatment Protocol (EAP) of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma

Ajai Chari, MD, Tomer M Mark, MD MSc, Amrita Krishnan, Keith Stockerl-Goldstein, Saad Z Usmani, MD FACP, Anil Londhe, Delores Etheredge, Hollee Parros, Sarah Fleming, Baolian Liu, Scott Freeman, Jon Ukropec, PhD, Thomas Lin, Sagar Lonial, MD FACP

Blood (2016) 128 (22): 2133.

https://doi.org/10.1182/blood.V128.22.2133.2133

Published: 2016

Journal Articles

Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma

Blood (2016) 128 (22): 2142.

https://doi.org/10.1182/blood.V128.22.2142.2142

Published: 2016

Journal Articles

Optimizing Progenitor Cell Mobilization in Patients with Myeloma: Effect of a Pre-Emptive Day 4 Plerixafor-Based Mobilization Algorithm

Omotayo O. Fasan, MBBS, MRCP, Saad Z Usmani, MD FACP, Danyu Sun, MD PhD, Ryan Jacobs, MD, Carlos Lee, BSc, Jigar Trivedi, MSc, PharmD, Eric Chow, PharmD, Dragos Plesca, PharmD, PhD, Manisha Bhutani, MD, Belinda R. Avalos, MD, Edward A. Copelan, MD FACP

Blood (2016) 128 (22): 2184.

https://doi.org/10.1182/blood.V128.22.2184.2184

Published: 2016

Journal Articles

Preliminary Results from a Phase Ib Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Paul G. Richardson, MD, Joseph Mikhael, MD, Saad Z Usmani, MD FACP, Noopur Raje, MD, William Bensinger, MD, Frank Campana, MD, Lei Gao, Franck Dubin, Claudine Wack, PhD, Kenneth C. Anderson, MD

Blood (2016) 128 (22): 2123.

https://doi.org/10.1182/blood.V128.22.2123.2123

Published: 2016

Journal Articles

Daratumumab in Combination with Lenalidomide Plus Dexamethasone Induces Clonality Increase and T-Cell Expansion: Results from a Phase 3 Randomized Study (POLLUX)

Christopher Chiu, PhD, Tineke Casneuf, Amy Axel, Andrew Lysaght, Jaime Bald, Nushmia Z Khokhar, Torben Plesner, Professor, Saad Z Usmani, MD FACP, Hartmut Goldschmidt, MD, Tahamtan Ahmadi, MD, Kenneth Chan, A. Kate Sasser

Blood (2016) 128 (22): 4531.

https://doi.org/10.1182/blood.V128.22.4531.4531

Published: 2016

Journal Articles

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Blood (2016) 128 (22): 976.

https://doi.org/10.1182/blood.V128.22.976.976

Published: 2016

Journal Articles

Fluorescence in Situ Hybridization (FISH) abnormalities and Baseline Clinical Features at Diagnosis in African American Multiple Myeloma Patients

Megan H Jagosky, MD, Kyle L Madden, BS, Blake B Goodbar, MD, Virginia Thurston, PhD, Manisha Bhutani, MD, Preeya Patel, BS, Myra M Robinson, Rupali Bose, Jill Eddy, Candice G Roth, RN, MSN, Lynn S Sanders, MSN, RN, OCN, James T Symanowski, PhD, Tammy D Cogdill, NP, Belinda R. Avalos, MD, Edward A. Copelan, MD FACP, Saad Z Usmani, MD FACP

Blood (2016) 128 (22): 2351.

https://doi.org/10.1182/blood.V128.22.2351.2351

Published: 2016

Journal Articles

Outcomes in Transplant Eligible Multiple Myeloma African American Patients Appear Similar to Caucasian Patients

Megan H Jagosky, MD, Kyle L Madden, BS, Myra M Robinson, Blake B Goodbar, MD, Manisha Bhutani, MD, Preeya Patel, BS, Rupali Bose, Jill Eddy, Sarah LeStrange, Candice G Roth, RN, MSN, Lynn S Sanders, MSN, RN, OCN, James T Symanowski, PhD, Tammy D Cogdill, NP, Dragos Plesca, PharmD, PhD, Belinda R. Avalos, MD, Edward A. Copelan, MD FACP, Saad Z Usmani, MD FACP

Blood (2016) 128 (22): 2352.

https://doi.org/10.1182/blood.V128.22.2352.2352

Published: 2016

Journal Articles

Establishment of Subspecialized Care in Hematologic Malignancies and a Hematopoietic Cell Transplantation Program

Edward A. Copelan, MD FACP, Jonathan M. Gerber, MD, Saad Z Usmani, MD FACP, Michael R. Grunwald, MD, Nilanjan Ghosh, MD PhD, Omotayo O. Fasan, MBBS, MRCP, Manisha Bhutani, MD, James T Symanowski, PhD, Derek Raghavan, MD PhD FACP, FRACP, FASCO, Belinda R. Avalos, MD

Blood (2016) 128 (22): 3580.

https://doi.org/10.1182/blood.V128.22.3580.3580

Published: 2016

Journal Articles

Distribution of Cytogenetic Abnormalities in African American Multiple Myeloma Patients May be Unique for Different Geographic Regions

Manisha Bhutani, MD, Preeya Patel, BS, Myra M Robinson, Rupali Bose, Kyle Madden, BS, Jill Eddy, Candice G Roth, RN, MSN, James Symanowski, Tammy Cogdill, NP, Jordan Robinson, PA-C, Belinda R Avalos, MD, Edward A. Copelan, MD, Saad Z Usmani, MD FACP

Blood (2015) 126 (23): 5337.

https://doi.org/10.1182/blood.V126.23.5337.5337

Published: 2015

Journal Articles

Expression and in Vitro Binding of Protease Activated Receptor1 (PAR1) with Novel Anti-PAR1 Molecules: Data on Fresh Myeloma Marrow Plasma Cells and Human Myeloma Cell Lines

Meral Beksac, MD, Pinar Ataca, MD, Berna Atesagaoglu, MD, Klara Dalva, Andry Nur Hidayat, Ismail Yalcin, Esin Yalcin Aki, Tulin Ozkan, Xenofon Papanikalaou, Saad Z Usmani, MD FACP, Erming Tian, PhD

Blood (2015) 126 (23): 4440.

https://doi.org/10.1182/blood.V126.23.4440.4440

Published: 2015

Journal Articles

Impact of Lenalidomide Maintenance Therapy on Immune Polarization and Activation in Multiple Myeloma

Manisha Bhutani, MD, David Foureau, PhD, Tammy Cogdill, NP, Kyle Madden, BS, Qing Zhang, PhD, Sarah A Baxter, PhD, Lawrence J Druhan, PhD, Nilanjan Ghosh, MD PhD, Belinda R Avalos, MD, Edward A. Copelan, MD, Saad Z Usmani, MD FACP

Blood (2015) 126 (23): 2966.

https://doi.org/10.1182/blood.V126.23.2966.2966

Published: 2015

NARROW

Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study

Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study

Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R MM), Indicates Preferential Expansion of CD8+ T Cell Central Memory Cell Subset

Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux

Peripheral Immune Profile and Minimal Residual Disease (MRD) Burden Following Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM)

Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients: The Insight-MM Study

Results of an Early Access Treatment Protocol (EAP) of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma

Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma

Optimizing Progenitor Cell Mobilization in Patients with Myeloma: Effect of a Pre-Emptive Day 4 Plerixafor-Based Mobilization Algorithm

Preliminary Results from a Phase Ib Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Daratumumab in Combination with Lenalidomide Plus Dexamethasone Induces Clonality Increase and T-Cell Expansion: Results from a Phase 3 Randomized Study (POLLUX)

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Fluorescence in Situ Hybridization (FISH) abnormalities and Baseline Clinical Features at Diagnosis in African American Multiple Myeloma Patients

Outcomes in Transplant Eligible Multiple Myeloma African American Patients Appear Similar to Caucasian Patients

Establishment of Subspecialized Care in Hematologic Malignancies and a Hematopoietic Cell Transplantation Program

Distribution of Cytogenetic Abnormalities in African American Multiple Myeloma Patients May be Unique for Different Geographic Regions

Expression and in Vitro Binding of Protease Activated Receptor1 (PAR1) with Novel Anti-PAR1 Molecules: Data on Fresh Myeloma Marrow Plasma Cells and Human Myeloma Cell Lines

Impact of Lenalidomide Maintenance Therapy on Immune Polarization and Activation in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only